Vetabolics is offering an at‑home urine screening test for dogs that the company says is intended to flag cancers — including hemangiosarcoma — at an early stage. The product, marketed as a non‑invasive canine health screening, combines owner‑collected urine samples with laboratory analysis driven by an artificial intelligence‑based diagnostic model.

The testing workflow begins with dog owners collecting a urine sample at home and submitting it to an offsite laboratory for analysis. Vetabolics describes the approach as translating observations about how dogs can detect disease by scent into a repeatable diagnostic workflow: rather than relying solely on imaging or tissue biopsies, the company’s model seeks early chemical or molecular patterns in urine that an algorithm can classify.

According to the company, the laboratory performs controlled analyses on the submitted samples and applies an AI diagnostic model to identify patterns that have been associated with cancer in prior work. Vetabolics frames the model as a way to systematize scent‑based signals into measurements that can be evaluated in a lab setting. The company positions the test as a complement to routine veterinary care and as a tool for serial monitoring — enabling repeated screenings over time without invasive procedures.

Vetabolics highlights hemangiosarcoma among the cancers the screening is intended to flag. The company emphasizes that the screening looks for early chemical or molecular signatures in urine that may be present before imaging or biopsy would typically be used, with the stated goal of providing an additional route for risk assessment that can prompt veterinary follow‑up when warranted.

The company’s offering and its underlying approach were profiled in recent coverage on Canine Health Screening Tests, and Vetabolics provides additional detail on its own website. That coverage and the company’s materials underline the two primary elements of the service: an at‑home collection step that reduces the need for in‑clinic sampling, and a laboratory‑based AI analysis meant to translate scent‑inspired signals into a consistent diagnostic output.

Industry interest in non‑invasive, laboratory‑based tests for early cancer detection in pets has been growing, and Vetabolics’ launch reflects a broader push toward easier sampling and remote diagnostics in the veterinary market. The company’s screening is among a range of products and concepts that have appeared recently, all aiming to make routine monitoring simpler for owners while providing veterinarians with additional information to inform clinical decisions.

Vetabolics presents the test as a screening tool rather than a replacement for veterinary examinations or definitive diagnostic procedures. The company says the method is intended to help owners and veterinarians assess risk and identify cases that may warrant further diagnostic workup. By offering an at‑home collection option, Vetabolics aims to enable serial monitoring that can be repeated over months or years as part of ongoing pet health management.

The company’s materials emphasize the controlled laboratory environment for analysis and the role of the AI model in classifying chemical or molecular patterns in urine samples. Vetabolics characterizes this combination of owner access and laboratory‑level analytics as a way to translate anecdotal and observational knowledge about canine scent detection into a repeatable, analytic test.

For more on the offering, Vet-Approved Screening Tests : Oncotect and Vetabolics’ website provide further detail on the company’s presentation of the test and its intended role in canine health screening.

Source

Original reporting: view the original article.